136-47-0
Product Name:
Tetracaine hydrochloride
Formula:
C15H25ClN2O2
Synonyms:
4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester;Amethocaine hydrochloride
Inquiry
CHEMICAL AND PHYSICAL PROPERTIES
| Solubility | >45.1 [ug/mL] (The mean of the results at pH 7.4) |
|---|---|
| Collision Cross Section | 172.6 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards] |
SAFETY INFORMATION
| Signal word | Danger |
|---|---|
| Pictogram(s) |
 Skull and Crossbones Acute Toxicity GHS06 |
| GHS Hazard Statements |
H301:Acute toxicity,oral H319:Serious eye damage/eye irritation H336:Specific target organ toxicity,single exposure; Narcotic effects |
| Precautionary Statement Codes |
P261:Avoid breathing dust/fume/gas/mist/vapours/spray. P264:Wash hands thoroughly after handling. P264:Wash skin thouroughly after handling. P270:Do not eat, drink or smoke when using this product. P271:Use only outdoors or in a well-ventilated area. P301+P310:IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing. |
COMPUTED DESCRIPTORS
| Molecular Weight | 300.82 g/mol |
|---|---|
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 9 |
| Exact Mass | 300.1604557 g/mol |
| Monoisotopic Mass | 300.1604557 g/mol |
| Topological Polar Surface Area | 41.6 Ų |
| Heavy Atom Count | 20 |
| Formal Charge | 0 |
| Complexity | 249 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 2 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Tetracaine hydrochloride is a calcium channel protein inhibitor and blocks voltage-sensitive release of Ca2+ from sarcoplasmic reticulum. Tetracaine hydrochloride is an inhibitor of Na+ CP type X α and Na+ CP type IV α.